raloxifene hydrochloride has been researched along with Rheumatism in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bannuru, RR; Buckley, L; Cannon, M; Fink, HA; Grossman, J; Guyatt, G; Hansen, KE; Humphrey, MB; Lane, NE; Magrey, M; McAlindon, T; Miller, AS; Miller, M; Morrison, L; Osani, M; Rao, M; Robinson, AB; Saha, S; Turgunbaev, M; Vaysbrot, E; Wolver, S | 1 |
| Ho, LY; Lee, HK; Ma, KM; Mok, CC; To, CH; Ying, KY; Yu, KL | 1 |
1 review(s) available for raloxifene hydrochloride and Rheumatism
| Article | Year |
|---|---|
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
Topics: Bone Density Conservation Agents; Calcium, Dietary; Consensus; Denosumab; Diphosphonates; Glucocorticoids; Humans; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Rheumatic Diseases; Rheumatology; Societies, Medical; Teriparatide; United States; Vitamin D | 2017 |
1 trial(s) available for raloxifene hydrochloride and Rheumatism
| Article | Year |
|---|---|
Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.
Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Drug Administration Schedule; Female; Glucocorticoids; Hip Joint; Humans; Lipids; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Prednisone; Raloxifene Hydrochloride; Rheumatic Diseases | 2011 |